Eurazeo: Novacap completes acquisition of PCI Synthesis
(CercleFinance.com) - Novacap has announced signing an agreement for the acquisition of PCI Synthesis, a US company that specialises in the development and custom manufacturing of pharmaceutical ingredients (CDMO).
PCI Synthesis offers its clients a wide range of services, such as research and process development, clinical development and commercial production of pharmaceutical active ingredients and other specialty intermediates.
The company's sales reach 32 million dollars.
PCI has benefited from significant growth in recent years, positioning itself as a strategic partner in the US pharmaceutical and biotech industries with a broad range of services and technologies, a high level of responsiveness and proven project management skills, the group said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
PCI Synthesis offers its clients a wide range of services, such as research and process development, clinical development and commercial production of pharmaceutical active ingredients and other specialty intermediates.
The company's sales reach 32 million dollars.
PCI has benefited from significant growth in recent years, positioning itself as a strategic partner in the US pharmaceutical and biotech industries with a broad range of services and technologies, a high level of responsiveness and proven project management skills, the group said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.